Introduction
N6-methyladenosine (m6A) is the most prevalent internal modification on eukaryotic mRNA, acting as a regulatory "tag" that influences mRNA stability and translation efficiency. While the core "writer" complex (METTL3/METTL14) is known to deposit these tags, the role of its largest component, VIRMA (Vir-like m6A methyltransferase associated), has remained largely elusive. Given its high expression in embryonic brains and various cancers, researchers investigated how VIRMA-mediated m6A modification influences the cellular machinery responsible for building ribosomes—the cell’s protein factories.
VIRMA as the Structural Scaffold
The study demonstrates that VIRMA is not merely an accessory but serves as the essential structural scaffold for the m6A writer complex. Depletion of VIRMA leads to the destabilization and degradation of the entire complex, including METTL3, METTL14, and WTAP. This collapse results in a dramatic (~60%) reduction in global mRNA m6A levels. Mapping the epitranscriptome via MeRIP-seq revealed over 8,000 "hypo-m6A" peaks, particularly in the 3' UTR regions, highlighting VIRMA's indispensable role in maintaining the m6A landscape.
Impact on Brain Development
To understand the physiological consequences of VIRMA loss, researchers employed a conditional knockout (cKO) mouse model (Emx1-Cre; Virma^fl/fl) to delete the gene in the forebrain. The resulting phenotype was severe: cKO mice exhibited a complete absence of the hippocampus and a significantly thinned cortex, with most animals dying by postnatal day 25. Cellular analysis showed that VIRMA deficiency leads to decreased proliferation and increased apoptosis of neural progenitor/stem cells (NPCs), establishing VIRMA as a critical factor for normal brain development.
Mechanistic Insights: The Paradox of mRNA Stability
The study uncovered a counterintuitive mechanism regarding mRNA stability. Typically, m6A tags target mRNAs for degradation via reader proteins like YTHDF2. In the absence of VIRMA, mRNAs encoding key ribosome biogenesis factors—such as Ncl, Rrp15, and Ppp38—fail to be methylated and thus persist longer than normal.
Paradoxically, this increased stability and subsequent over-expression of these factors disrupt the delicate stoichiometric balance required for ribosome assembly. This imbalance leads to an accumulation of ribosomal RNA (rRNA) precursors and a failure to produce mature, functional ribosomes. Polysome profiling and protein synthesis assays (SUnSET/OPP) confirmed a dramatic reduction in global translation rates in VIRMA-depleted cells.
Ribosomal Stress and the P53 Response
This failure in ribosome biogenesis triggers a "ribosomal stress" response, activating the P53 pathway. This cellular alarm system induces cell cycle arrest and programmed cell death (apoptosis), explaining the massive loss of NPCs and the resulting microcephaly. Importantly, this mechanism is conserved in human cancer cells. Experiments in breast (MCF7) and cervical (HeLa) cancer cell lines showed that VIRMA depletion similarly induces ribosomal stress and inhibits proliferation, suggesting a universal regulatory role.
Implications for Cancer Therapy
The link between VIRMA and ribosome biogenesis suggests a potential therapeutic vulnerability. Analysis of the Cancer Dependency Map (DepMap) revealed that VIRMA is highly co-dependent with genes involved in rRNA processing across hundreds of cancer cell lines. Because rapidly dividing cancer cells are heavily dependent on efficient protein synthesis, targeting VIRMA could provide a way to "starve" tumors by inducing lethal ribosomal stress.
Conclusion
This research establishes VIRMA-mediated m6A modification as a master regulator of the protein synthesis machinery. By ensuring the timely decay of ribosome biogenesis factors, VIRMA maintains the balance necessary for active translation during critical periods of development and in oncogenic growth. These findings not only advance our understanding of epitranscriptomic regulation but also highlight VIRMA as a promising target for future neurodevelopmental and anti-cancer interventions.
Summary updated